Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Clinical trial NCT07524322 · RECRUITING

Trial details

NCT number: NCT07524322
Sponsor: Regor Pharmaceuticals Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Breast Cancer Ovarian Cancer Endometrial Cancer PIK3CA Mutation HER2- Negative Breast Cancer Advanced Breast Cancer Unresectable Solid Tumor Hormone Receptor Positive Tumor Cervical Cancer

Start date: 2026-06-01
Primary completion: 2028-04-01
Enrollment: 63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.